COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, we review the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexisting thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/155446/1/Bikdeli-2020-COVID-19 and Thrombotic or Thromb.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/155446/3/DeepBluepermissions_agreement-CCBYandCCBY-NC_ORCID_Barnes.docxhttps://deepblue.lib.umich.edu/bitstream/2027.42/155446/4/license_rdf.rdfDescription of Bikdeli-2020-COVID-19 and Thrombotic or Thromb.pdf : ArticleDescription of DeepBluepermissions_agreement-CCBYandCCBY-NC_ORCID_Barnes.docx : Deep Blue sharing agreemen

Phtisie aiguë / par L. Dreyfus-Brisac,... et I. Bruhl,...

Collection : Bibliothèque médicale Charcot-DeboveContient une table des matièresAvec mode text

Tricuspid Regurgitation: predicting the need for intervention, procedural success, and recurrence of disease

Interest in tricuspid valve pathology has rapidly expanded in response to reported poor clinical outcome for functional tricuspid regurgitation and the limited indications and options for treatment. In the past few years, different transcatheter technologies have emerged as alternatives to conventional surgery to serve this untreated high-risk population. In this review, the authors explore the indications for intervention in tricuspid regurgitation according to current guidelines, the published research to support the expansion of these indications including the role of transcatheter interventions, and the risk factors for therapy failure, which may help define the appropriate patient population for treatment

Time and rate measures in choice transitions

Three experiments with pigeons studied the relation between time and rate measures of behavior under conditions of changing preference. Experiment 1 studied a concurrent chain schedule with random-interval initial links and fixed-interval terminal links; Experiment 2 studied a multiple chained random-interval fixed-interval schedule; and Experiment 3 studied simple concurrent random-interval random-interval schedules. In Experiment 1, and to a lesser extent in the other two experiments, session-average initial-link wait-time differences were linearly related to session-average response-rate differences. In Experiment 1, and to a lesser extent in Experiment 3, ratios of session-average initial-link wait times and response rates were related by a power function. The weaker relations between wait and response measures in Experiment 2 appear to be due to the absence of competition between responses. In Experiments 1 and 2, initial-link changes lagged behind terminal-link changes. These findings may have implications for the relations between fixed- and variable-interval procedures and suggest that more attention should be paid to temporal measures in studies of free-operant choice